MedTrace Logo

Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program

NCT00969865 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2017-11-20

No results posted yet for this study

Summary

This study will evaluate the effectiveness of an individualized approach to diagnosing and/or treating atherosclerosis. This will be done by combining genetic information, lifestyle information, participant education, and imaging tests to track diagnoses, therapies, and treatment on two groups: 1) Standard Management Group (diagnosed and/or treated according to standard of care) and 2) Individualized Management Group (standard of care plus genetic testing and coronary artery calcium scans).

Conditions

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Piedmont Healthcare

    lead OTHER

Principal Investigators

  • Joseph Miller, MD · Piedmont Heart Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00969865 on ClinicalTrials.gov